Anne Wilhøft Kristensen from Dansk Center for Partikelterapi - Danish Centre for Particle Therapy presents: This Danish PhD project explored the decision-making process in clinical trial participation, highlighting the barriers for patients and physicians. #PatientInvolvement #ClinicalTrials
Onkologi DK
Bog- og tidsskriftsforlag
Virum, Hovedstaden 540 følgere
Få seneste forskningsnyt inden for onkologi
Om os
Gå ikke glip af det nyeste fra onkologi. Læs nye artikler skrevet af specialister, se MEDtalks hvor der bl.a. præsenteres den nyeste forskning, lyt til MEDcasts hvor der diskuteres patient cases, tag faglige test og læs magasiner inden for dit fagområde.
- Websted
-
https://bpno.dk/specialer/onkologi/
Eksternt link til Onkologi DK
- Branche
- Bog- og tidsskriftsforlag
- Virksomhedsstørrelse
- 11-50 medarbejdere
- Hovedkvarter
- Virum, Hovedstaden
- Grundlagt
- 2019
Opdateringer
-
Mansoor Raza Mirza from Rigshospitalet is looking forward to ESMO 2024. He eagerly awaits new data on the effectiveness of combining chemoradiation with pembrolizumab for locally advanced cervical cancer, which shows a potential new standard of care, long-term efficacy data from the PRIMA study in ovarian cancer, and insights into the DUO-E trial in endometrial cancer. #ESMO24 #Cancer
Mansoor Raza Mirza: ESMO is the Meeting Which Brings New Data for Forever Practice-Changing Trials
https://bpno.dk
-
Lars Boesen from Københavns Universitet - University of Copenhagen presents: This new study reports that MRI-guided transperineal prostate biopsies performed without antibiotics is a safe and effective alternative to traditional transrectal biopsies, as it significantly reduce infection risks. #ProstateBiopsy #PatientSafety #Antibiotics
Get in the Perineum! – Refinement of Prostate Biopsy Technique for Patient Safety and Antibiotic Stewardship
https://bpno.dk
-
This study, presented by Jerome Leow, aimed to compare the prognostic impact of PSMA PET staging versus conventional imaging on pelvic node-positive prostate cancer outcomes. Results showed that PSMA PET staging significantly improved biochemical failure-free survival and overall survival at four years, suggesting better prognosis and challenging the notion of incurability in these patients. #Prostatecancer #Treatments
PSMA PET Staging Significantly Improves Prognosis in Pelvic Node-Positive Prostate Cancer
https://bpno.dk
-
🚀 Skal du være til Dansk Aften ESMO 2024 i Barcelona? Mød danske specialister og hør de nyeste highlights fra #ESMO24: 👤Mødeleder og lungekræft: Jens Benn Sørensen Brystkræft: Louise Wichmann Matthiessen Blærekræft: Dag Stormoen Malignt melanom: TBD Endometrie- og ovariecancer: Mansoor Raza Mirza Øvre gastrointestinal kræft: Camilla Qvortrup Efter de faglige oplæg og diskussioner inviterer BestPractice Nordic til middag, hvor vi kan fortsætte de gode samtaler. 👉Tilmeld dig nu: https://lnkd.in/dJ5HsuUk
🌟BestPractice Nordic inviterer til Dansk Aften ESMO 2024 i Barcelona!🌟 Deltag i et spændende i Barcelona, hvor vi samler danske specialister, der deltager på ESMO, til en faglig og social begivenhed med diskussioner, perspektiveringer og netværk. Programmet byder på en videnskabelig opsummering af nyheder og highlights fra de største cancersygdomme, efterfulgt af engagerende diskussioner. Oplægsholderne vil præsentere deres perspektiver og højdepunkter, efterfulgt af en hyggelig middag, hvor vi kan fortsætte samtalerne. 👉Tilmeld dig nu og vær med til Dansk Aften ESMO 2024 her: https://lnkd.in/dbF8Czrz #DanskAften #ESMO24 #Netværk #Faglighed #Barcelona
Dette indhold er ikke tilgængeligt her
Få adgang til dette indhold og meget mere i LinkedIn-appen
-
In this MEDtalk, Louise Bjørn Larsen presents a study that sought to determine the benefit of imatinib in patients with wild-type GIST. The results show that the median PFS on first-line imatinib was 6 months in advanced wild-type GIST, but with great variability. #DSKO24
Treatment with Imatinib in Patients with Wild-Type GIST
https://bpno.dk
-
Listen to Thorgerdur Palsdottir elaborate on how they use the Capio model for prostate cancer diagnostics at Capio St: Göran Prostate Cancer Centre in Sweden. She describes their diagnosis and treatment process and emphasizes the use of the Stockholm3 test and MRI. This has resulted in high rates of clinically significant detection of prostate cancer, shorter treatment times and reduced costs compared to other centres. 🔗See more from the American Society of Clinical Oncology (ASCO) 2024 congress; https://lnkd.in/dYfkuK_B #ASCO24 #ProstateCancer
The Capio Model for Prostate Cancer Diagnostics
https://bpno.dk
-
Dr. Joaquim Bellmunt from the Dana-Farber Cancer Institute Inc, Harvard Medical School, summarizes findings from the JAVELIN 100 study presented at American Society of Clinical Oncology (ASCO) 2024. The study evaluated the efficacy of maintenance avelumab plus Best Supportive Care versus Best Supportive Care alone in patients with advanced urothelial cancer who had low tumor burden. The study show significantly prolonged OS and PFS and manageable toxicity for those patients receiving avelumab 🔗See more from our coverage of the ASCO 2024 congress; https://lnkd.in/dYfkuK_B #ASCO24 #Bladdercancer #Treatments
First-line Maintenance therapy with Avelumab show significantly prolonged OS and PFS in Patients with Advanced Urothelial Cancer with Low Tumor Burden
https://bpno.dk
-
Dr. Umang Swami from Huntsman Cancer Institute, University of Otah, presents in this MEDtalk a study that compared cabozantinib alone versus cabozantinib with immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma patients. The results showed no significant benefit from adding PD-1/PD-L1 inhibitors, suggesting that single-agent cabozantinib is sufficient and avoids extra toxicity. #Kidneycancer #Oncology
Single-Agent Cabozantinib is Sufficient and Avoids Extra Toxicity in Metastatic Clear Cell Renal Cell Carcinoma Patients
https://bpno.dk
-
ALK-rearrangements are oncogenic drivers in 3-5% of NSCLC and various cancers. Today, six TKI inhibitors are available for patients with advanced ALK-rearranged non-small cell lung cancer. In this MEDtalk, Edyta Maria Urbanska from Rigshospitalet gives an overview of new tendencies in the development of ALK-TKIs. #LungCancer #Treatment #ALK
New Tendencies in Development of ALK-TKIs for Treatment of ALK-Rearranged NSCLC
https://bpno.dk